KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Gross Profit: 2017-2024

Historic Gross Profit for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$16.9 million.

  • Aquestive Therapeutics' Gross Profit fell 8.83% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.4 million, marking a year-over-year decrease of 175.86%. This contributed to the annual value of -$16.9 million for FY2024, which is 156.68% down from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Gross Profit is -$16.9 million, which was down 156.68% from $29.8 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Gross Profit peaked at $35.8 million during FY2021, and registered a low of -$16.9 million during FY2024.
  • Moreover, its 3-year median value for Gross Profit was $28.3 million (2022), whereas its average is $13.7 million.
  • In the last 5 years, Aquestive Therapeutics' Gross Profit spiked by 499.85% in 2021 and then tumbled by 156.68% in 2024.
  • Aquestive Therapeutics' Gross Profit (Yearly) stood at -$9.0 million in 2020, then skyrocketed by 499.85% to $35.8 million in 2021, then decreased by 21.06% to $28.3 million in 2022, then increased by 5.15% to $29.8 million in 2023, then plummeted by 156.68% to -$16.9 million in 2024.